+83,964.9%
BBY vs GSK
+1,741.1%
+82,223.8%
-80.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.7% | -0.1% | -0.6% | -0.7% |
| 7D | -2.8% | -1.3% | -1.4% | -2.3% |
| 30D | +11.6% | +2.7% | +8.8% | +10.6% |
| 3M | +20.8% | +2.7% | +18.1% | +19.8% |
| 6M | +88.0% | +3.3% | +84.7% | +85.2% |
| YTD | +60.5% | +6.5% | +54.1% | +55.6% |
| 1Y | +43.8% | +10.7% | +33.1% | +37.4% |
| 3Y | +79.2% | +64.4% | +14.8% | +44.4% |
| 5Y | -3.3% | +46.7% | -50.0% | -20.3% |
| 10Y | +267.4% | +109.4% | +158.1% | +161.5% |
| All | +83,964.9% | +1,741.1% | +82,223.8% | +29,245.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling